Byondis
![THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ISSUED A COMPLETE RESPONSE LETTER CONCERNING [VIC-]TRASTUZUMAB DUOCARMAZINE, A PRODUCT DEVELOPED BY BYONDIS.](https://pharmtales.com/wp-content/uploads/2023/06/FDA-Issues-Response-Letter-on-Byondis-Trastuzumab-Duocarmazine.jpg)
FDA Issues Response Letter on Byondis’ Trastuzumab Duocarmazine
SG Tylor
Byondis B.V., a Dutch clinical-stage biopharmaceutical company specializing in precision medicines, has announced today that the U.S. Food and Drug ...
most recent
Latest News, Deals, Pharma
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Pharma, Clinical Trials, Latest News
Vertex Halts Phase 2 Lung Therapy, Reevaluates DMD Drug’s Clinical Path
Latest News, Clinical Trials, Pharma
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Latest News, Pharma
J&J MedTech Plans US Clinical Trials for Ottava Surgical Robot in Late 2024
